FDA Critic Sees More Drug Drama
Updated from 1:47 p.m. EST
A veteran researcher for the Food and Drug Administration told legislators Thursday that the recent withdrawal of Vioxx by Merck (MRK) represents "a profound regulatory failure" that could easily be repeated with other drugs."
The scientist, David J. Graham, who was the lead author in a study criticizing Vioxx, said he was pressured by senior management to alter his conclusions that Vioxx represented a greater cardiovascular risk than Celebrex, a similar arthritis treatment and pain reliever made by Pfizer (PFE).
Graham was the first witness in a hearing held by the Senate Finance Committee, which is investigating the Vioxx case as well as the FDA's drug approval and drug safety review efforts. The last witness of the day was Raymond V. Gilmartin, chairman and CEO of Merck, who said the company acted quickly and responsibly once carefully designed medical research showed that Vioxx presented a greater risk of heart attack and strokes among people who used the drug for more than 18 months. If the trial had ended at 18 months, he noted, there would have been no statistically significant difference in risk between patients who took Vioxx and patients who received a placebo.Graham said the FDA is "incapable of protecting America against another Vioxx" because of bureaucratic torpor and calcified policies. Graham noted that during his FDA career, he has recommended that 12 drugs be pulled from the market, adding that only two remain on the market. Calling Vioxx "a national disaster" and arguing that the drug should have been removed from the market as far back as four years ago, Graham directed most of his anger at the FDA. He said the agency creates a bureaucratic culture in which "post-marketing safety is an afterthought."
Merck's Message"The Food and Drug Administration approved Vioxx only after Merck had extensively studied the medicine and found it to be safe and effective," said Gilmartin, repeating comments that he has made in news conferences and analysts' meetings since Merck pulled Vioxx from the market on Sept. 30. "Merck continued to extensively study Vioxx after it was approved for marketing to gain more clinical information about the medicine." For the past six years, he added, " we have promptly disclosed the results of numerous Merck-sponsored studies to the FDA, physicians, the scientific community and the media and participated in a balanced, scientific discussion of its risks and benefits," he added. Gilmartin's comments were presented to the Senate Finance Committee, whose chairman, Sen. Charles E. Grassley (R., Iowa), has criticized the actions of the company as well as the Food and Drug Administration. "Mr. Chairman, Merck believed wholeheartedly in Vioxx," Gilmartin said. "I believed wholeheartedly in Vioxx. In fact, my wife was a user of Vioxx until the day we withdrew it from the marketplace." Grassley's committee is examining Merck's handling of Vioxx amid accusations by some prominent cardiologists and medical journals that Merck should have withdrawn the drug as early as four years ago because there was enough evidence for the company to act. Merck has been the subject of blistering editorials recently in The New England Journal of Medicine and the British medical journal The Lancet. The committee also is investigating the FDA's relationship with Merck, in light of complaints by some scientists and legislators that the FDA was too slow to act and too cozy with the company. "Consumers should not have to second-guess" the safety of a drug, Grassley said Thursday. "There is more to learn about this drug disaster." The Justice Department and the Securities and Exchange Commission are investigating Merck's actions. The withdrawal of Vioxx has provoked a flood of lawsuits: Merck said it knows of 375 as of Oct. 31. Three credit rating companies -- Moody's Investors Service, Fitch Ratings and Standard & Poor's -- have recently cut the company's rating by several notches primarily due to the loss of Vioxx $2.5 billion annual revenue -- and the uncertainty over the legal costs. The company's stock has lost about 40% of its value. Shares were down 13 cents, or 0.5%, to $27.21 on Thursday.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV